Skip to main content
. 2021 May 8;14(5):445. doi: 10.3390/ph14050445

Figure 2.

Figure 2

Kaplan-Meier survival plots for overall survival (a) and progression-free survival (b) in both patients who treated with nivolumab for non-small cell lung cancer with antibiotics (ABX group, n = 70) or without antibiotics (NoABX group, n = 70).